With chemotherapy in the treatment of uterine sarcoma, cyclophosphamide, vincristine, adriamycin and triazene microphone amine CYVADIC programme reported that more efficient up to 15% to 55%. 1997, Jelic, such as the use of cisplatin, epirubicin PE programme that is forward-looking, were treated 106 cases of soft tissue sarcoma patients, the CR for 13%, PR for 41 percent of the total effective rate of 54 percent, significantly higher than the effect of Adriamycin chemotherapy alone group.
Uterine sarcoma is the early transfer of blood characteristics. It was reported in the literature, even clinical I, II period of uterine sarcoma, after three years also have higher rates of lung metastases, which uterine leiomyosarcoma up 40.7 percent. Therefore, after the main support to the systemic chemotherapy treatment to delay tumor recurrence, has received increasing attention.
1. Chemotherapy drugs alone
At present, the effect of chemotherapy is relatively sure of the embryo in the womb of malignant mixed tumor. U.S. GOG done a two prospective, random study.
(1) alone ifosfamide embryo in the treatment of malignant tumors in 29 cases of mixed daily 1.5 mg/m2, intravenous infusion for 5 days. The total efficiency of 32.2 percent, the rate of complete remission (CR) of 17.9%, partial response rate (PR) was 14.3%.
(2) single-agent cisplatin in the treatment of malignant tumor hybrid embryo of the 63 cases, each for 50 mg/m2, to 1 mg per minute rate of intravenous infusion every three weeks 1. The total effective rate of 19 per cent, of which CR to 8%, PR 11%. Therefore, the United States Gynecologic Oncology Association of Jurists under the two research findings, recommend the use of ifosfamide or Ifosfamide + cisplatin in the treatment of malignant uterine tumors in the embryo of mixed.
Adriamycin chemotherapy uterine sarcoma is worthy of attention in the drug activity. GOG the United States had observed the time-consuming 11 to 60 mg/m2 per Adriamycin treatment of I, II of the 156 cases of uterine sarcoma patients, although the results showed that doxorubicin is the trend of delaying tumor recurrence, but the difference was not significant . 1988, Piver forward-looking, such as the treatment of 19 patients with stage I uterine sarcoma patients were randomly divided into simple operation group, surgery Jiae Adriamycin chemotherapy, doxorubicin dosage for each of the 75 mg/m2 or 60 mg/m2, Intravenous injection every four weeks a course of treatment, for six courses. The results, the operation group of 5-year survival rate was 36 percent, surgery Jiae Adriamycin chemotherapy group of 5-year survival rate was 63 percent. Another report, adriamycin treatment of advanced and recurrent uterine leiomyosarcoma efficiency of 25%.
2. Chemotherapy
With chemotherapy in the treatment of uterine sarcoma, cyclophosphamide, vincristine, adriamycin and triazene microphone amine CYVADIC programme reported that more efficient up to 15% to 55%. 1997, Jelic, such as the use of cisplatin, epirubicin PE programme that is forward-looking, were treated 106 cases of soft tissue sarcoma patients, the CR for 13%, PR for 41 percent of the total effective rate of 54 percent, significantly higher than the effect of Adriamycin chemotherapy alone group. PE programme than CYVADIC simple clinical application of the programme, randomized studies show that the effect is also better.
3. Progesterone treatment
1990, Wade and other detected 60 cases of different types of organizations of uterine sarcoma expression of estrogen and progesterone receptors, found that the patients in the uterine sarcoma, endometrial stromal sarcoma and malignant uterine in the embryo of mixed Of estrogen receptor-positive rate of 60%, 78% and 42%. Progesterone receptor-positive rate of 60%, 22% and 19%. Therefore, the auxiliary progesterone treatment of uterine sarcoma should have a certain effect. The current clinical observation showed that progesterone to endometrial stromal sarcoma and malignant uterine tumors in the embryo of the mixed effect to a certain extent, endometrial stromal sarcoma efficiency as high as 50 percent. Sun love of progesterone treatment, such as the use of low-grade endometrial stromal sarcoma has also made good effect. Therefore, some scholars have suggested that endometrial stromal sarcoma and progesterone not only to be used for the treatment of recurrence or metastasis, but also as adjuvant treatment after one of the basic.
Uterine sarcoma is the early transfer of blood characteristics. It was reported in the literature, even clinical I, II period of uterine sarcoma, after three years also have higher rates of lung metastases, which uterine leiomyosarcoma up 40.7 percent. Therefore, after the main support to the systemic chemotherapy treatment to delay tumor recurrence, has received increasing attention.
1. Chemotherapy drugs alone
At present, the effect of chemotherapy is relatively sure of the embryo in the womb of malignant mixed tumor. U.S. GOG done a two prospective, random study.
(1) alone ifosfamide embryo in the treatment of malignant tumors in 29 cases of mixed daily 1.5 mg/m2, intravenous infusion for 5 days. The total efficiency of 32.2 percent, the rate of complete remission (CR) of 17.9%, partial response rate (PR) was 14.3%.
(2) single-agent cisplatin in the treatment of malignant tumor hybrid embryo of the 63 cases, each for 50 mg/m2, to 1 mg per minute rate of intravenous infusion every three weeks 1. The total effective rate of 19 per cent, of which CR to 8%, PR 11%. Therefore, the United States Gynecologic Oncology Association of Jurists under the two research findings, recommend the use of ifosfamide or Ifosfamide + cisplatin in the treatment of malignant uterine tumors in the embryo of mixed.
Adriamycin chemotherapy uterine sarcoma is worthy of attention in the drug activity. GOG the United States had observed the time-consuming 11 to 60 mg/m2 per Adriamycin treatment of I, II of the 156 cases of uterine sarcoma patients, although the results showed that doxorubicin is the trend of delaying tumor recurrence, but the difference was not significant . 1988, Piver forward-looking, such as the treatment of 19 patients with stage I uterine sarcoma patients were randomly divided into simple operation group, surgery Jiae Adriamycin chemotherapy, doxorubicin dosage for each of the 75 mg/m2 or 60 mg/m2, Intravenous injection every four weeks a course of treatment, for six courses. The results, the operation group of 5-year survival rate was 36 percent, surgery Jiae Adriamycin chemotherapy group of 5-year survival rate was 63 percent. Another report, adriamycin treatment of advanced and recurrent uterine leiomyosarcoma efficiency of 25%.
2. Chemotherapy
With chemotherapy in the treatment of uterine sarcoma, cyclophosphamide, vincristine, adriamycin and triazene microphone amine CYVADIC programme reported that more efficient up to 15% to 55%. 1997, Jelic, such as the use of cisplatin, epirubicin PE programme that is forward-looking, were treated 106 cases of soft tissue sarcoma patients, the CR for 13%, PR for 41 percent of the total effective rate of 54 percent, significantly higher than the effect of Adriamycin chemotherapy alone group. PE programme than CYVADIC simple clinical application of the programme, randomized studies show that the effect is also better.
3. Progesterone treatment
1990, Wade and other detected 60 cases of different types of organizations of uterine sarcoma expression of estrogen and progesterone receptors, found that the patients in the uterine sarcoma, endometrial stromal sarcoma and malignant uterine in the embryo of mixed Of estrogen receptor-positive rate of 60%, 78% and 42%. Progesterone receptor-positive rate of 60%, 22% and 19%. Therefore, the auxiliary progesterone treatment of uterine sarcoma should have a certain effect. The current clinical observation showed that progesterone to endometrial stromal sarcoma and malignant uterine tumors in the embryo of the mixed effect to a certain extent, endometrial stromal sarcoma efficiency as high as 50 percent. Sun love of progesterone treatment, such as the use of low-grade endometrial stromal sarcoma has also made good effect. Therefore, some scholars have suggested that endometrial stromal sarcoma and progesterone not only to be used for the treatment of recurrence or metastasis, but also as adjuvant treatment after one of the basic.
Posts
No comments:
Post a Comment